 |
Osteoprotegerin
Research News and Information
Definition of 'Osteoprotegerin'A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B. Common names: Osteoprotegerin; Osteoclastogenesis Inhibitory Factor; Receptors, Tumor Necrosis Factor, Member 11b; Follicular Dendritic Cell-Derived Receptor-1; Follicular Dendritic Cell Derived Receptor 1; Tumor Necrosis Factor Receptor Superfamily, Member 11b; FDCR-1 Protein; FDCR 1 Protein; OCIF Protein |
Sunday, November 22, 2009
CCR5 down-regulates osteoclast function in orthodontic tooth movement.
30 Oct 2009 
During orthodontic tooth movement, there is local production of chemokines and an influx of leukocytes into the periodontium. CCL5 plays an important role in osteoclast recruitment and activation. This study aimed to investigate whether the ... Read more...
7 Oct 2009 Receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG), a decoy receptor of RANKL, maintain bone mass by regulating the differentiation of osteoclasts, which are bone-resorbing cells. Endochondral bone ossification and ... Read more...
Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin.
6 Oct 2009 Autoantibodies against osteoprotegerin, which block the inhibitory effect of osteoprotegerin on signaling by the receptor activator of nuclear factor (NF)-kappaB (RANK), were identified in a man with celiac disease who presented with severe ... Read more...
Latest indexed articles for 'Osteoprotegerin'
These are the very latest articles for this heading:
- CCR5 down-regulates osteoclast function in orthodontic tooth movement. 30 Oct 2009
- Accelerated cartilage resorption by chondroclasts during bone fracture healing in osteoprotegerin-deficient mice. 7 Oct 2009
- Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. 6 Oct 2009
- Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating. 29 Sep 2009
- Newer biomarkers in heart failure. 29 Sep 2009
- Influence of lipopolysaccharide and interleukin-6 on RANKL and OPG expression and release in human periodontal ligament cells. 29 Sep 2009
- A single-nucleotide polymorphism in the gene encoding osteoprotegerin is associated with diastolic blood pressure in older men. 22 Sep 2009
- Direct effects of osteoprotegerin on human bone cell metabolism. 9 Sep 2009
- Osteoblast and osteoclast differentiation in an in vitro three-dimensional model of bone. 30 Aug 2009
- Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. 30 Aug 2009
- Identification and functional analyses of molecular haplotypes of the human osteoprotegerin gene promoter. 4 Aug 2009
- Dynamic changes in bone metabolism in the rat temporomandibular joint after molar extraction using bone scintigraphy. 30 Jul 2009
- Pathways in external apical root resorption associated with orthodontia. 30 Jul 2009
- Detection of root resorption using dentin and bone markers. 30 Jul 2009
- Markers of bone destruction and formation and periodontitis in type 1 diabetes mellitus. 30 Jul 2009
- Basic synovial biology and immunopathology in psoriatic arthritis. 30 Jul 2009
- NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors. 30 Jul 2009
- Interaction of human recombinant tumor necrosis factor-related apoptosis-inducing ligand and osteoprotegerin could contribute to enhancement of the erosive processes induced by human synovial cells.
30 Jul 2009 - Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. 30 Jul 2009
- Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis. 30 Jul 2009
See a longer list of these articles.
Technical information about 'Osteoprotegerin'
Definition: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.
Registry Number: 0
Descriptor UI: D053244
Alternative terms: Osteoprotegerin; Osteoclastogenesis Inhibitory Factor; Receptors, Tumor Necrosis Factor, Member 11b; Follicular Dendritic Cell-Derived Receptor-1; Follicular Dendritic Cell Derived Receptor 1; Tumor Necrosis Factor Receptor Superfamily, Member 11b; FDCR-1 Protein; FDCR 1 Protein; OCIF Protein; Tumor Necrosis Factor Receptor 11b;
Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;
Tree Number: D12.776.543.750.705.852.760.949.249;
History Note: 2007(1997)